Knight Therapeutics Inc. (TSX:GUD)

Market Cap	834.16M +39.9%
Revenue (ttm)	510.45M +36.9%
Net Income	5.61M -49.3%
EPS	0.06 -43.4%
Shares Out	98.25M
PE Ratio	150.23
Forward PE	69.31
Dividend	n/a
Ex-Dividend Date	n/a

Volume	107,109
Average Volume	94,548
Open	8.59
Previous Close	8.64
Day's Range	8.33 - 8.59
52-Week Range	5.66 - 8.90
Beta	0.04
RSI	66.88
Earnings Date	May 7, 2026

About Knight Therapeutics

Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 830
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: GUD